 SAN FRANCISCO, June 21, 2021 GLOBE NEWSWIRE -- Nurix Therapeutics, Inc. Nasdaq: NRIX, a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product development. Ms. Wolff brings to Nurix over 30 years of leadership experience in oncology and immunology most recently from Principia Biopharma Inc., where she served as chief development officer and formerly senior vice president of strategy and operations overseeing Principias portfolio including BTK targeted agents. During her tenure at Principia, she successfully guided drug pipeline strategy and led many functions over time, including the companys manufacturing and technical operations, regulatory and quality, clinical operations, project and portfolio management, medical affairs, commercial and communications functions until its acquisition by Sanofi in September, 2020. 